CureVac | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Sunday
June 01, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SUNDAY, JUNE 01, 2025

CureVac

Photo: BSS/AFP
Coronavirus chronicle

Covid vaccine from Germany's CureVac just 48% effective: final results

The European Union has secured up to 405 million doses of the CureVac vaccine

Representational Image. Photo: Reuters
Coronavirus chronicle

CureVac crashes after crucial Covid-19 vaccine trial disappoints

Representational Image. Photo: Reuters
Coronavirus chronicle

CureVac says mass vaccine rollout thrown into doubt by US restrictions

Representational Image. Photo: Reuters
Coronavirus chronicle

CureVac starts review process in Switzerland for Covid-19 vaccine hopeful

Representational Image. Photo: Reuters
Coronavirus chronicle

CureVac's Covid-19 vaccine attracts rising interest

Representational Image. Photo: Reuters
Coronavirus chronicle

CureVac says aiming for pivotal vaccine trial read-out early in Q2

Representational Image. Photo: Reuters
Coronavirus chronicle

CureVac says preliminary trials show Covid-19 vaccine effective against variants

Representational Image. Photo: Reuters
Coronavirus chronicle

GSK, CureVac say to develop vaccine targeting Covid variants

Representational Image. Photo: Reuters
Coronavirus chronicle

Bayer and Rentschler to help produce CureVac's Covid-19 shot

Representational Image. Photo: Reuters
Coronavirus chronicle

Bayer aims to help CureVac with Covid-19 vaccine output, says CEO

Representational Image. Photo: Reuters
Coronavirus chronicle

CureVac strikes Covid-19 vaccine alliance with Bayer

Photo: Collected.
Coronavirus chronicle

EU could pay over $10 billion for Pfizer and CureVac vaccines 

Representational Image. Photo: Reuters
World+Biz

CureVac hiking capacity to 300 million Covid-19 doses in 2021

  • Show More
  • loading...
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net